Quinazoline Derivatives Irreversible EGFR Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current reversible EGFR tyrosine kinase inhibitors face challenges with drug resistance and limited efficacy in long-term treatment of non-small cell lung cancer, as they compete with high intracellular ATP concentrations, leading to reduced effectiveness in animal models.
Innovation Solution
A quinazoline derivative with Pan-HER irreversible inhibition function is developed, which forms a Michael addition reaction with cysteine residues on the EGFR, providing sustained inhibition of EGFR and HER family kinases, thereby overcoming drug resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If reversible EGFR tyrosine kinase inhibitors are used, then initial therapeutic response is achieved, but drug resistance develops after several months of treatment
Solution Approach 1:
The patent changes the fundamental mechanism parameter from reversible inhibition to irreversible inhibition. The compound forms a covalent bond with cysteine residue in the ATP-binding site of EGFR, transforming the inhibition from temporary and competitive to permanent and non-competitive, thereby eliminating drug resistance that develops with reversible inhibitors.
Solution Approach 2:
The patent extracts the reversible binding characteristic from the inhibitor design and replaces it with irreversible covalent bonding. By removing the reversible interaction mechanism and implementing direct covalent bond formation with the cysteine residue, the compound achieves sustained inhibition without the resistance development inherent in reversible inhibitors.
2Reliability
If reversible tyrosine kinase inhibitors are used, then kinase inhibition is achieved, but competition with high intracellular ATP concentration reduces effectiveness
Solution Approach 1:
The patent extracts the competitive binding mechanism and replaces it with non-competitive covalent bonding. The compound directly bonds to the cysteine residue in the ATP-binding site, removing the need to compete with ATP for binding. This eliminates the harmful effect of ATP competition while maintaining reliable kinase inhibition.
Solution Approach 2:
Instead of the inhibitor attempting to displace ATP from the binding site (competitive mechanism), the patent inverts the approach by having the inhibitor form a direct covalent bond with the cysteine residue in the ATP-binding site. This inversion of the binding strategy eliminates the competitive disadvantage imposed by high intracellular ATP concentrations.
3Productivity
If long-term treatment with reversible inhibitors is administered, then initial tumor growth inhibition is achieved, but acquired drug resistance occurs
Solution Approach 1:
The patent applies preliminary irreversible bonding to the cysteine residue in the ATP-binding site, preventing the development of drug resistance before it can occur. By establishing permanent covalent bonds with the target kinase, the compound ensures sustained tumor growth inhibition without the acquired resistance that develops with reversible inhibitors during long-term treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The quinazoline derivative achieves enhanced antineoplastic effects by maintaining kinase inhibition, reducing drug resistance, and demonstrating improved therapeutic outcomes in preclinical models.
Implementation Method 1
A quinazoline derivative with Pan-HER irreversible inhibition function is developed, which forms a Michael addition reaction with cysteine residues on the EGFR
Data Source
AI summary
The invention relates to quinazoline derivatives substituted by aniline which are represented by the below formula (I), pharmaceutical acceptable salts and stereoisomer thereof, wherein these groups of R1, R2, R3, R4, R5, R6, L and n have the meanings given in the specification. The invention also relates to preparation methods, pharmaceutical compositions, pharmaceutical preparation and the use for preparation of medicine of treating excessive hyperplasia and chronic obstructive pulmonary disease and uses for treating excessive hyperplasia and chronic obstructive pulmonary disease thereof.